England - West Midlands • Corporate and commercial

DLA Piper

We only have limited information for this firm. Consider the following firms which have provided more information:

Rated by clients for its ‘breadth of knowledge and experience across the team’, DLA Piper continues to demonstrate its capabilities in high-value, cross-border work – particularly in the industrials, consumer goods, and life sciences sectors. The corporate team is headed up by Tim Lake, an expert in industrials and manufacturing sector work, who regularly advises on big-ticket, multi-jurisdictional acquisitions in the space. Commercial practice head Ryan Harrison is similarly well-versed in cross-border matters, particularly in the retail and consumer goods industries. Charles Cook’s broad transactional focus sees him working with leading conglomerates from the worlds of pharmaceuticals, energy, and automotive manufacturing, while global consumer goods co-chair Noel Haywood’s recent workload includes high-value deals in the food sector. Other names to note include Robert Newman, an equity capital markets (ECM) specialist, and Simon Wright, recommended for his hospitality and leisure acumen.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

  • ‘Noel Haywood is always available, even when matters are being dealt with by others.'

  • 'Vicky Hughes combines knowledge of the law with the utmost common sense. She is especially good at explaining complicated documents in the simplest possible terms and provides great reassurance.’

Abbreviated data is displayed for this firm.

Key clients

  • 2 Sisters Food Group
  • Adenia Partners

Abbreviated data is displayed for this firm.

Work highlights

  • Advised MKS Instruments, Inc. on its acquisition of Atotech Limited, backed by buyout firm Carlyle Group Inc. The equity value of the transaction is USD5.1 billion and the enterprise value of the transaction is USD6.5 billion.
  • Represented Intercept Pharmaceuticals, Inc. on its disposal of nine of its foreign subsidiaries and its rights regarding Intercept’s international operations, including a license to commercialize Ocaliva® (obeticholic acid) outside of the US, to Advanz Pharma. The transaction is valued at up to US$450 million.

Abbreviated data is displayed for this firm.